Published • loading... • Updated
Cancer jab can eradicate entire tumours in patients, trial shows
In a 102-patient trial, amivantamab shrank or erased tumours in 43 patients and cleared them completely in 15.
- On Sunday, researchers will present results at the American Society of Clinical Oncology meeting in Chicago showing amivantamab shrank or eradicated head and neck tumours in 43 of 102 patients, including 15 complete responses.
- This triple-action jab blocks EGFR and MET pathways while activating the immune system, targeting HPV-negative head and neck cancers that typically resist standard chemotherapy and immunotherapy.
- Carl Walsh joined the OrigAMI-4 trial at the Royal Marsden in July 2025, reporting his diet and speech returned to normal; most patients experienced mild side-effects, with fewer than one in 10 stopping treatment.
- Describing the responses as 'unprecedented,' Kevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, noted this represents a significant step forward for thousands of patients annually.
- Johnson is evaluating amivantamab in about 60 clinical trials across multiple cancer types, with similar results reported in lung cancer, signaling potential to extend beyond current head and neck applications.
Insights by Ground AI
16 Articles
16 Articles
New cancer vaccine eliminates tumors in clinical trial
Medical researchers have reported a major breakthrough in the development of a new cancer vaccine that has shown encouraging results in patients with advanced and recurring cancers. The vaccine, known as Amivantamab, is currently being tested in clinical trials across 11 countries. Researchers say early results have been highly promising, with some patients experiencing complete disappearance of their tumors. The treatment is administered throug…
Coverage Details
Total News Sources16
Leaning Left5Leaning Right2Center2Last UpdatedBias Distribution56% Left
Bias Distribution
- 56% of the sources lean Left
56% Left
L 56%
C 22%
R 22%
Factuality
To view factuality data please Upgrade to Premium
